Pricing Log in Create free account

Urogen Pharma (URGN) vs Xencor, Inc. (XNCR)

Urogen Pharma and Xencor, Inc. are both Biotechnology companies. Urogen Pharma and Xencor, Inc. are of similar size ($1.8B and $1.8B). Urogen Pharma grew revenue faster over the last twelve months: 100.3% against −28.6%. Urogen Pharma has the higher net margin (−51.7% vs −155.6%) and the higher return on invested capital (0.00% vs −288.7%). Across the 17 metrics below, Urogen Pharma leads on 13 and Xencor, Inc. on 4.

Valuation

Metric URGN XNCR Biotechnology median
P/E n/m n/m 8.50
P/S 9.23 16.58 9.71
P/B n/m 3.46 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m n/m 0.64
EV/Sales 9.66 13.38 9.21
Earnings yield (5.73%) (9.46%) (33.15%)
Free cash flow yield (9.14%) (12.02%) (25.50%)

Profitability

Metric URGN XNCR Biotechnology median
Gross margin 90.85% 100.00% 65.16%
Operating margin (35.32%) (205.84%) 0.00%
Net margin (51.73%) (155.59%) 0.00%
Free cash flow margin (84.32%) (198.42%) 0.00%
Return on equity 86.49% (29.07%) (56.36%)
Return on assets (42.33%) (20.36%) (48.04%)
Return on invested capital 0.00% (288.71%) 0.00%

Growth

Metric URGN XNCR Biotechnology median
Revenue growth (TTM) 100.27% (28.56%) 6.02%
EPS growth (last fiscal year) (7.77%) 65.36% 30.26%
Revenue growth, 5-year CAGR 56.22% 0.47% 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric URGN XNCR Biotechnology median
Debt to equity (1.45) 0.00 0.00
Current ratio 3.80 6.39 4.72
Net debt to EBITDA 0.00 2.51 0.96

Dividend

Metric URGN XNCR Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric URGN XNCR Biotechnology median
Market cap 1.79b 1.78b 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack